Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data
Abstract Tamoxifen, a selective estrogen receptor modulator, is used to treat hormone receptor‐positive breast cancer. Tamoxifen acts as a prodrug, with its primary therapeutic effect mediated by its principal metabolite, endoxifen. However, tamoxifen has complex pharmacokinetics involving several d...
Saved in:
Main Authors: | Bianca Kruger (Author), Delva Shamley (Author), Nyarai Desiree Soko (Author), Collet Dandara (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reply to "Inadequate representation of individuals of African ancestry in pharmacogenetics of tamoxifen research"
by: Bianca Kruger, et al.
Published: (2024) -
Inadequate representation of individuals of African ancestry in pharmacogenetics of tamoxifen research
by: Keneuoe Cecilia Nthontho, et al.
Published: (2024) -
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
by: Jeanine Marie Nardin, et al.
Published: (2020) -
Etiology of aggressive periodontitis in individuals of African descent
by: Akihiro Yoshida, et al.
Published: (2021) -
A Reconsideration Of Tamoxifen Use for Breast Cancer
by: Peng-Hui Wang, et al.
Published: (2007)